French antiviral drug is ruled ineffective
BMJ 1994; 309 doi: https://doi.org/10.1136/bmj.309.6948.148 (Published 16 July 1994) Cite this as: BMJ 1994;309:148- A Dorozynski
French health authorities have declared ineffective an antiviral drug that has been prescribed to hundreds of patients with AIDS over the past six years. The drug, PB-100, was designed by a former researcher at the Pasteur Institute, Mirko Beljanski, and has become increasingly popular with doctors and patients, although its prescription and marketing have never been authorised. A number of patients are still receiving it, and it is far from certain that the so called “Beljanski affair” is over.
Beljanski, a doctor of biology, joined the Pasteur Institute in 1948, when he was 25, to work under Professor Pierre Lepine, who developed the French polio vaccine. Later he moved to the molecular biology department …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.